SCHEMBL6609872

SCHEMBL6609872

COC(=O)C1CN(S(=O)(=O)c2ccc(C)cc2)c2ccccc2CN1S(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
KMT2A Q03164 3/20 0.56
MMP1 P03956 8/20 0.55
MMP9 P14780 8/20 0.55
MMP13 P45452 8/20 0.55
ADAM17 P78536 8/20 0.55
MMP2 P08253 4/20 0.54
ANPEP P15144 2/20 0.54
CYP19A1 P11511 1/20 0.49
LMNA P02545 1/20 0.45
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6611272 0.91 MMP1 (0.67) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL6644952 0.90 MMP1 (0.68) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL6609838 0.87 MMP1 (0.72) ALDH1A1MMP1MMP9MMP13ADAM17
SCHEMBL6609963 0.85 MMP1 (0.53) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL6614240 0.84 MMP13 (0.70) MMP1MMP9MMP13ADAM17
SCHEMBL5655828 0.84 MMP1 (0.68) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL6641084 0.82 MMP1 (0.66) MMP1MMP9MMP13ADAM17LMNA
SCHEMBL6610757 0.82 MMP1 (0.64) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL6612774 0.82 MMP1 (0.55) ALDH1A1KMT2AMMP1MMP9MMP13
SCHEMBL27573230 0.82 MMP1 (0.82) MMP1MMP9MMP13ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed